Urgent.News

What's breaking now, across thousands of outlets.

Business

Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs

Demis Hassabis’ Isomorphic Labs has raised a massive $5bn Series C funding round, just six months after raising $2.1bn in a Series B funding, as it looks to leverage AI to power a new generation of me...

Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs

Demis Hassabis' Isomorphic Labs has secured a staggering $5 billion in Series C funding, just six months after raising $2.1 billion in a Series B round. The new investment, co-led by California-based Greenoaks and Sequoia, will bolster Isomorphic's efforts to use AI to revolutionize drug discovery.

Isomorphic, founded by Hassabis, was spun out of Google DeepMind and specializes in leveraging AI to accelerate the development of new medicines. The company's software, including the Nobel Prize-winning AlphaFold, which predicts protein structures, forms the foundation of its work. Isomorphic is targeting treatments for cancer and immune disorders.

The company is developing its proprietary drug design engine, IsoDDE, and a pipeline of therapeutic candidates designed with AI to create the next generation of medicines. Isomorphic plans to expand its focus on new biology with advanced AI models to advance a variety of therapeutic classes.

To achieve these goals, Isomorphic is creating a partner ecosystem aimed at understanding mechanistic disease biology. The company will use the $5 billion to support AI advancement and clinical development infrastructure as it advances drug candidates through clinical trials.

Hassabis, Isomorphic's founder and CEO, emphasized that the funding will help build foundational biology models, deepen understanding of systemic diseases, and bring the company's therapeutic programs closer to clinical trials. Max Jaderberg, Isomorphic's president, highlighted the team's progress, stating that their models are generating repeatable scientific advancements that translate into better molecular profiles and the potential for new medicines.

The interdisciplinary teams at Isomorphic, comprising machine learning researchers and top drug hunters, are rapidly solving complex biological problems that have long stumped traditional research methods. This infusion of capital from investors including Andreessen Horowitz, Thrive Capital, Alphabet, Alphabet's GV and CapitalG, Tamesek, and the Sovereign AI fund will accelerate Isomorphic's mission to revolutionize drug discovery with the power of AI.

Written by urgent.news from Tech.eu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at tech.eu →

More in Business

11 easy Thanksgiving dessert recipes that aren't pumpkin pie

Pumpkin pie is a staple on Thanksgiving, but there are other fan-favorite desserts you can make that your family and friends will love.

  • Offer pumpkin pie alternatives like baked apples with vanilla ice cream
  • Elevate simple brownies with premium ingredients like nuts
  • Create easy desserts without an oven, such as apple crisp

More from Tuesday 17 November →